Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tscan Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TCRX
Nasdaq
8731
https://www.tscan.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tscan Therapeutics Inc
TScan Therapeutics Announces Closing of Upsized Public Offering
- Apr 19th, 2024 2:05 pm
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- Apr 17th, 2024 4:30 am
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- Apr 16th, 2024 8:25 pm
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- Apr 16th, 2024 8:01 pm
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
- Apr 8th, 2024 12:00 pm
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 11:00 am
Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%
- Mar 26th, 2024 12:48 pm
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
- Mar 17th, 2024 6:58 pm
TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline
- Mar 7th, 2024 6:44 pm
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
- Mar 6th, 2024 1:15 pm
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 6th, 2024 12:00 pm
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 28th, 2024 12:00 pm
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
- Feb 26th, 2024 12:00 pm
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
- Feb 19th, 2024 10:49 am
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
- Feb 14th, 2024 12:00 pm
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
- Feb 6th, 2024 12:00 pm
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
- Jan 29th, 2024 12:00 pm
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
- Jan 18th, 2024 12:00 pm
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
- Jan 4th, 2024 12:00 pm
Timothy Barberich Bought 41% More Shares In TScan Therapeutics
- Dec 23rd, 2023 12:32 pm
Scroll